Pricing Log in Create free account

Aligos Therapeutics, Inc. (ALGS) vs TransCode Therapeutics Inc. (RNAZ)

Aligos Therapeutics, Inc. and TransCode Therapeutics Inc. are both Biotechnology companies. Aligos Therapeutics, Inc. is the larger, with a market value of $33.7M against $30.5M — 1.1× the size. TransCode Therapeutics Inc. has the higher net margin (0.00% vs −241.0%) and the higher return on invested capital (0.00% vs −3,379.3%). Across the 12 metrics below, TransCode Therapeutics Inc. leads on 8 and Aligos Therapeutics, Inc. on 4.

Valuation

Metric ALGS RNAZ Biotechnology median
P/E n/m n/m 8.50
P/S 1.61 n/m 9.71
P/B 1.59 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.10 0.64
EV/Sales 0.65 n/m 9.21
Earnings yield (150.21%) (3,080.59%) (33.15%)
Free cash flow yield (186.46%) (1,390.70%) (25.50%)

Profitability

Metric ALGS RNAZ Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (250.63%) 0.00% 0.00%
Net margin (241.01%) 0.00% 0.00%
Free cash flow margin (299.90%) 0.00% 0.00%
Return on equity (113.59%) 429.61% (56.36%)
Return on assets (75.57%) (58.12%) (48.04%)
Return on invested capital (3,379.28%) 0.00% 0.00%

Growth

Metric ALGS RNAZ Biotechnology median
Revenue growth (TTM) 893.01% — 6.02%
EPS growth (last fiscal year) 88.30% 96.02% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALGS RNAZ Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.19 1.97 4.72
Net debt to EBITDA 0.87 0.64 0.96

Dividend

Metric ALGS RNAZ Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ALGS RNAZ Biotechnology median
Market cap 33.66m 30.48m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack